Peptide • Aging & cellular biology
Elamipretide
Also called SS-31; MTP-131
What it is, the potential benefits being studied, and what the evidence supports right now.
Well established•Used medically for a specific purpose
01 • Start here
Potential benefits being studied.
Barth syndrome in patients who weigh at least 30 kilograms, plus investigational research in other mitochondrial diseases.
- Cellular energy & aging
- Condition-specific research
02 • Why it stands out
The simple explanation.
Elamipretide is designed to work at the inner mitochondrial membrane—the energy-producing center of the cell.
03 • Research highlight
Why researchers are interested.
It is a mitochondria-focused peptide with a specific medical use and broader interest around cellular energy and muscle function.
Evidence detailsStudy limits, status, and safety context
Study summary: FDA granted accelerated approval to Forzinity in September 2025 for a narrow Barth syndrome population. Continued approval may depend on confirmatory evidence.
What to keep in mind: This approval does not establish general energy, exercise, anti-aging, or longevity benefits, or support other elamipretide products and uses.
Potential benefits describe research questions, not a promise that a product will produce the same result in a person.